Skip to main content

Table 2 Data from patient self-report questionnaires

From: Long-term follow-up of thalamic deep brain stimulation for essential tremor – patient satisfaction and mortality

A: Medication for tremor

Number of patients N = 26

Yes

No

Unknown

Preoperative

12 (46)

11 (42)

3 (12)

Postoperative

5 (19)

16 (62)

5 (19)

At follow-up

9 (35)

12 (46)

5 (19)

B: Patient self-report

 

All (N = 26)

  

VIM-DBS effect on tremor postoperative

8.5 (0.1-10)

  

VIM-DBS effect on tremor at follow-up

7.4 (0.1-10)

  

Overall satisfaction with VIM-DBS

10 (0–10)

  

C: Most common adverse effects with VIM-DBS

Variable

All

  

Number of patients

26

  

Dysarthria

17 (65)

  

Headache

9 (35)

  

Parestesia

6 (23)

  

Abnormal taste

8 (31)

  

Dizziness

5 (19)

  

Discomfort tongue

4 (15)

  

Reduced balance or coordination

4 (15)

  

Other

8 (31)

  
  1. Patient self-report from follow-up questionnaire. Median follow-up 6.0 years (range, 2–16).
  2. 2A. Data are given in number of patients = n (%) reporting use of medication for tremor including betablockers, antiepileptics, benzodiazepines.
  3. 2B. VAS scale 1–10, where 0 is no effect of VIM-DBS on tremor and 10 is maximum effect.
  4. 2C. Data given in number of patients = n (%) experiencing adverse effects.
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us